文献速递鼻科

过敏原免疫治疗对术后中央气道过敏性疾病患者的影响

The effect of allergen immunotherapy in patients with central compartment atopic disease post-surgery.
PubMed 文献 · Int Forum Allergy Rhinol · 2024-09-27

回顾性队列评估过敏原免疫治疗(AIT)对术后尘螨致敏的中央气道过敏性疾病(CCAD)患者的效果。86例患者中37%(n=32)接受AIT,术后12个月AIT组中鼻甲水肿(≥弥漫性15.6% vs 52.9%,p<0.01)和鼻用糖皮质激素冲洗≥4次/周比例(37.5% vs 79.6%,p<0.01)均低于非AIT组,鼻部症状评分无显著差异。结论认为手术和药物治疗有效,加用AIT改善过敏表现并减少局部用药。

要点

  • 术后12个月AIT组中鼻甲弥漫性水肿比例15.6%,低于非AIT组的52.9%(p<0.01)。
  • AIT组术后12个月糖皮质激素冲洗≥4次/周比例为37.5%,低于非AIT组的79.6%(p<0.01)。
  • 两组SNOT-22鼻部症状评分无显著差异(21.1±17.1 vs 20.1±21.6,p=0.83)。

核心结论

  • 手术和药物治疗对CCAD有效,加用AIT可改善过敏表现并减少局部治疗强度。
  • 作者指出需要更长期研究来证明进一步的免疫调节作用。

研究设计与样本

  • 回顾性队列研究,纳入接受手术治疗的尘螨致敏、表型为CCAD的CRSwNP患者86例(41±14岁,64%女性)。
  • 按是否在手术诊疗中启动AIT分为两组,所有AIT患者均在手术前开始免疫治疗,AIT组占37%(n=32)。
  • 主要终点为术后12个月中鼻甲水肿再形成;次要终点为糖皮质激素冲洗使用(<4次/周 vs ≥4次/周,%)和SNOT-22鼻部维度评分。

主要发现

  • 基线特征除结膜症状外两组相似,AIT组结膜症状更多(72% vs 45%,p=0.02)。
  • 术后12个月AIT组中鼻甲水肿(≥弥漫性)比例为15.6%,低于非AIT组的52.9%(p<0.01)。
  • 术后12个月AIT组糖皮质激素冲洗≥4次/周比例为37.5%,低于非AIT组的79.6%(p<0.01)。
  • 两组SNOT-22鼻部症状评分相似(21.1±17.1 vs 20.1±21.6,p=0.83)。

局限性

  • 原文结论指出需要更长期研究来证明进一步的免疫调节作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effect of allergen immunotherapy (AIT) on patients with central compartment atopic disease (CCAD) and house dust mite (HDM) sensitization post-surgery. METHODS: A retrospective cohort of surgically treated, HDM-sensitized CRSwNP patients phenotyped as CCAD was assessed. Patients were divided into two groups based on whether they had AIT commenced as part of their surgical care. All AIT patients started immunotherapy prior to their surgery. The primary endpoint was reformation of middle turbinate (MT) edema 12 months postsurgery. Secondary endpoints were corticosteroid irrigation use (<4 times/week vs. ≥4 times/week, %) and the rhinologic domain of the 22-item sino-nasal outcome test (SNOT-22). Demographic characteristics, concomitant asthma, smoking status, history of aspirin-exacerbated respiratory disease, conjunctival symptoms, polysensitization, serum eosinophils (cell × 109/L), tissue eosinophilia (% > 100/HPF), and serum IgE (kU/L) were also recorded. RESULTS: Eighty-six CCAD patients were assessed (41 ± 14 yrs, 64% female). AIT was applied in 37% (n = 32). Baseline features were similar apart from greater conjunctival symptoms (72 vs. 45%, p = 0.02) in the AIT group. At 12 months post-surgery, the AIT group has less MT edema (% ≥ diffuse 15.6 vs. 52.9, p < 0.01). Patients on AIT also had less pharmacotherapy requirements at 12 months (% ≥ 4/week, 37.5 vs. 79.6%, p < 0.01). The rhinologic symptoms were similar (21.1 ± 17.1 vs. 20.1 ± 21.6, p = 0.83). CONCLUSIONS: Surgery and pharmacotherapy are effective in managing CCAD, but the addition of AIT improved allergic phenomenon and allowed de-escalation of topical therapy. Longer term studies are required to demonstrate further immunomodulation.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Meerwein CM, Sacks PL, Ho J, et al. The effect of allergen immunotherapy in patients with central compartment atopic disease post-surgery. Int Forum Allergy Rhinol. 2024. PMID: 39331586. doi:10.1002/alr.23459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。